Array BioPharma (ARRY) stock price, revenue, and financials

Array BioPharma market cap is $6.5 b, and annual revenue was $173.77 m in FY 2018

$6.5 B

ARRY Mkt cap, 10-Jun-2019

$64.7 M

Array BioPharma Revenue Q3, 2019
Array BioPharma Gross profit (Q3, 2019)63.6 M
Array BioPharma Gross profit margin (Q3, 2019), %98.4%
Array BioPharma Net income (Q3, 2019)-37.5 M
Array BioPharma EBIT (Q3, 2019)-37.5 M
Array BioPharma Cash, 31-Mar-201996.6 M
Array BioPharma EV6.5 B

Array BioPharma Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

42.1m51.9m137.9m150.9m173.8m

Revenue growth, %

23%166%

General and administrative expense

21.9m31.4m36.3m39.3m58.5m

Operating expense total

117.7m130.3m220.1m252.9m303.7m

EBIT

(75.6m)3.3m(82.2m)(102.1m)(129.9m)

EBIT margin, %

(180%)6%(60%)(68%)(75%)

Interest expense

9.7m10.2m10.9m12.3m10.8m

Interest income

77.0k68.0k243.0k796.0k4.5m

Pre tax profit

(145.0m)

Income tax expense

2.3m

Net Income

(85.3m)9.4m(92.8m)(116.8m)(147.3m)

Array BioPharma Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

68.6m55.7m56.6m125.9m114.7m

Accounts Receivable

5.4m6.3m39.3m31.3m32.1m

Inventories

5.2m6.4m6.1m

Current Assets

121.7m191.0m155.3m270.2m451.5m

PP&E

8.2m5.1m6.7m8.1m7.1m

Total Assets

139.1m198.2m168.9m279.1m460.4m

Accounts Payable

7.0m4.6m10.1m8.6m14.1m

Short-term debt

2.5m

Current Liabilities

52.7m42.4m52.4m69.6m95.9m

Long-term debt

104.0m107.3m93.4m

Non-Current Liabilities

112.0m113.1m154.4m197.9m144.7m

Total Debt

104.0m107.3m95.9m

Total Liabilities

164.8m155.6m206.8m267.4m240.6m

Additional Paid-in Capital

652.7m711.7m763.3m930.3m1.3b

Retained Earnings

(717.9m)(708.6m)(801.4m)(918.7m)(1.1b)

Total Equity

(25.7m)42.7m(37.9m)11.7m219.7m

Debt to Equity Ratio

0.4 x

Debt to Assets Ratio

0.2 x

Financial Leverage

-5.4 x4.6 x-4.5 x23.8 x2.1 x

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

65.0m47.2m52.2m46.8m68.1m141.5m56.4m57.3m62.5m65.8m62.8m83.7m295.4m65.1m73.9m130.5m147.1m96.6m

Accounts Receivable

1.0m5.7m4.4m6.0m4.9m2.1m13.5m64.8m62.9m33.9m43.1m32.5m26.6m30.0m44.2m44.4m22.2m31.7m

Inventories

4.4m

Current Assets

134.2m128.5m118.1m122.8m150.8m196.6m179.6m191.9m187.5m158.0m263.9m247.0m493.8m453.9m487.8m476.2m530.8m493.9m

PP&E

9.1m8.4m7.8m7.8m8.1m7.5m5.0m5.7m6.5m7.3m7.4m8.5m7.6m7.2m7.6m6.9m6.9m7.0m

Total Assets

152.6m146.3m135.2m135.3m163.6m208.4m186.8m199.9m196.2m166.9m272.2m256.2m502.3m462.8m497.0m484.2m549.0m567.0m

Accounts Payable

3.1m4.0m7.0m5.2m9.3m7.6m6.5m12.1m15.6m5.9m6.5m7.8m8.9m11.0m11.7m14.6m10.4m9.1m

Current Liabilities

51.9m38.3m45.9m56.6m67.9m44.9m49.3m53.0m59.5m64.2m64.4m71.3m90.9m73.6m85.1m84.8m84.2m86.7m

Long-term debt

100.2m101.4m102.7m105.3m108.8m110.4m112.0m115.4m117.5m119.4m123.3m93.3m94.6m131.1m132.7m134.2m

Non-Current Liabilities

113.9m113.4m112.6m116.3m109.6m113.4m113.4m141.0m151.5m154.8m155.8m157.2m184.8m147.1m146.8m180.4m179.4m178.7m

Total Debt

100.2m101.4m102.7m105.3m108.8m110.4m112.0m115.4m117.5m119.4m123.3m93.3m94.6m131.1m132.7m134.2m

Total Liabilities

165.8m151.7m158.5m172.9m177.6m158.3m162.7m194.0m211.0m219.0m220.2m228.5m275.7m220.7m231.9m265.2m263.6m265.4m

Additional Paid-in Capital

595.7m619.9m626.8m653.9m687.2m696.7m753.5m759.5m761.4m777.7m905.2m916.7m1.2b1.2b1.3b1.3b1.4b1.4b

Retained Earnings

(648.4m)(664.8m)(689.7m)(745.5m)(754.1m)(695.8m)(729.6m)(753.7m)(776.4m)(830.0m)(853.3m)(889.1m)(956.7m)(990.7m)(1.0b)(1.1b)(1.1b)(1.1b)

Total Equity

(13.2m)(5.3m)(23.3m)(37.6m)(13.9m)50.2m24.1m5.9m(14.8m)(52.1m)52.1m27.7m226.6m242.2m265.2m219.1m285.4m301.6m

Debt to Equity Ratio

18.8 x0.4 x

Debt to Assets Ratio

0.6 x0.2 x

Financial Leverage

-11.6 x-27.3 x-5.8 x-3.6 x-11.8 x4.2 x7.7 x34 x-13.3 x-3.2 x5.2 x9.2 x2.2 x1.9 x1.9 x2.2 x1.9 x1.9 x

Array BioPharma Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(85.3m)9.4m(92.8m)(116.8m)

Depreciation and Amortization

4.5m3.7m1.5m2.1m

Accounts Receivable

4.2m(7.6m)(33.0m)8.0m

Inventories

Accounts Payable

Cash From Operating Activities

(71.7m)(5.8m)(70.1m)(39.4m)

Purchases of PP&E

(2.6m)(2.5m)(3.2m)(3.5m)

Cash From Investing Activities

2.5m66.0m(58.1m)

Cash From Financing Activities

77.1m50.9m5.0m166.8m

Interest Paid

4.3m4.5m4.5m4.4m

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(15.7m)(32.1m)(57.0m)(27.6m)(36.2m)22.1m(21.0m)(24.2m)(22.7m)(28.6m)(23.3m)(35.3m)(72.0m)(94.9m)(24.8m)(36.2m)(73.7m)

Depreciation and Amortization

1.1m2.4m3.6m876.0k1.8m2.8m473.0k1.1m1.7m533.0k1.1m1.6m

Accounts Receivable

8.6m3.9m5.2m(571.0k)551.0k(3.4m)(7.2m)64.8m62.9m33.9m43.1m32.5m26.6m1.3m(12.9m)(12.3m)9.8m424.0k

Accounts Payable

12.1m15.6m5.9m6.5m7.8m8.9m

Cash From Operating Activities

(1.1m)(34.3m)(49.4m)(18.8m)(16.8m)21.5m(19.2m)(70.2m)(91.2m)(34.8m)(43.4m)(87.4m)

Purchases of PP&E

(198.0k)(725.0k)(1.4m)(483.0k)(1.7m)(2.1m)(411.0k)(212.0k)(1.1m)(265.0k)(843.0k)(1.5m)

Cash From Investing Activities

(10.8m)(25.8m)(11.6m)(3.0m)(15.0m)(246.9m)(258.2m)13.7m(32.9m)(84.6m)

Cash From Financing Activities

16.3m46.6m52.4m45.0k31.3m38.8m664.0k256.1m297.3m36.8m108.7m153.9m

Interest Paid

124.0k2.1m2.2m121.0k2.2m2.3m121.0k2.2m2.3m1.2m3.2m3.7m

Array BioPharma Ratios

USDY, 2019

EV/EBIT

-286 x

EV/CFO

-122.5 x

Financial Leverage

1.9 x

Array BioPharma Employee Rating

3.533 votes
Culture & Values
3.3
Work/Life Balance
3.7
Senior Management
2.7
Salary & Benefits
3.8
Career Opportunities
3.1
Source